Aerovate Therapeutics Revenue 2020-2025 | JBIO
Aerovate Therapeutics revenue from 2020 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Aerovate Therapeutics Annual Revenue
(Millions of US $) |
| 2024 |
$0 |
| 2023 |
$0 |
| 2022 |
$0 |
| 2021 |
$0 |
| 2020 |
$0 |
| 2019 |
$0 |
Aerovate Therapeutics Quarterly Revenue
(Millions of US $) |
| 2025-03-31 |
|
| 2024-12-31 |
|
| 2024-09-30 |
|
| 2024-06-30 |
|
| 2024-03-31 |
|
| 2023-12-31 |
|
| 2023-09-30 |
|
| 2023-06-30 |
|
| 2023-03-31 |
|
| 2022-12-31 |
|
| 2022-09-30 |
|
| 2022-06-30 |
|
| 2022-03-31 |
|
| 2021-12-31 |
|
| 2021-09-30 |
|
| 2021-06-30 |
|
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.010B |
$0.000B |
|
Aerovate Therapeutics Inc. is a clinical stage biopharmaceutical company. It focused on developing drugs for cardiopulmonary disease. The company's product pipeline consist AV-101. Aerovate Therapeutics Inc. is based in BOSTON.
|
